Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR1 K656E |
| Therapy | Pemigatinib |
| Indication/Tumor Type | diffuse astrocytoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 K656E | diffuse astrocytoma | predicted - sensitive | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FIGHT-207), Pemazyre (pemigatinib) treatment demonstrated safety in previously treated patients with advanced solid tumors harboring a kinase domain mutation or a variant of unknown significance in FGFR1, FGFR2, or FGFR3, and resulted in an objective response rate of 3.8% (1/26, partial responses), including a partial response with a progression-free survival of 8.0 months in a patient with diffuse astrocytoma harboring FGFR1 K656E (PMID: 38710951; NCT03822117). | 38710951 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38710951) | Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. | Full reference... |